A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce ...

AstraZeneca has gained approval from the European Commission (EC) for its oral therapy, Tagrisso (osimertinib), to treat ...

Exons are coding sections of an RNA transcript, or the DNA encoding it, that are translated into protein. Exons can be separated by intervening sections of DNA that do not code for proteins, known ...

At ASCO, the stellar PFS data sparked speculation that Tagrisso will become the standard of care in this type of early lung ...

The drug – formerly known as SRP-5051 – is a more potent version of Exondys 51 (eteplirsen), an exon-skipping therapy that can be used to treat around 13% of the population with the muscle ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Monday that the European Commission has approved Tagrisso (osimertinib) to ...

Avidity Biosciences' AOC platform shows promising results for genetic diseases, making it a strong buy with potential upside ...

EDO51, an investigational therapy for Duchenne muscular dystrophy (DMD), and is still ongoing in the United Kingdom.

NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...

Tagrisso has been approved in the European Union for the treatment of adult patients with locally advanced, unresectable ...

The FDA issued a complete response letter for the BLA submission of subcutaneous amivantamab for EGFR-mutated NSCLC, citing ...